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Abstract: Immune responses against pathogens re-
quire fine regulation to avoid excessive inflammation,
which could be harmful to the host. Moreover, the
immune system must be tolerant to nonpathogenic
antigens to prevent allergy, autoimmunity, and
transplant rejection. There is accumulating evi-
dence that interactions between dendritic cells
(DC) and regulatory T (Treg) cells play a crucial
role in the balance between immune response and
tolerance. Communications between these cells are
complex, bidirectional, and mediated by soluble or
cell surface molecules. The maturation status of
DC, which may be influenced by different micro-
environmental factors, is considered as an impor-
tant checkpoint for the induction of peripheral
tolerance through modifications of the activation
status of T cells. Moreover, several lines of exper-
imental evidence suggest that different subsets or
the functional status of DC are also involved in the
promotion of Treg cell differentiation. A better
knowledge of the regulatory mechanisms of the
immune response induced or inhibited by DC via
their interactions with Treg cells could be relevant
for the development of new, immunotherapeutic
approaches. J. Leukoc. Biol. 82: 781–794; 2007.
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INTRODUCTION
The adaptive immune system is a highly effective system
specialized to protect the host from dangerous pathogens.
Therefore, the immune system distinguishes not only self from
foreign structures but also harmful foreign pathogens from
innocuous antigens to prevent self-destructive immune re-
sponses. Moreover, under infectious conditions, negative reg-
ulation also prevents excessive inflammatory responses to in-
vading microorganisms, thus reducing host tissue damage and
providing sufficient time to develop a long-lasting memory.
Unfortunately, these negative regulatory processes are also
heavily exploited by invading pathogens for their own survival.
Among the important players in immune suppression are the
regulatory T (Treg) cells and specialized subsets of dendritic
cells (DC). Indeed, the functional properties of DC are tradi-
tionally associated with the efficient induction of primary T cell
responses. However, increasing evidence exists that DC are
also involved in the induction and maintenance of antigen-
specific peripheral T cell tolerance by acting on Treg cells.
This article aims to report recent developments in the role of
different DC subsets in tolerance, their interactions with Treg
cells, and the positive and negative aspects of these bidirec-
tional cell communications.
TOLEROGENIC DC
In addition to their central role in initiating adaptive immu-
nity to infections and other nonself antigens, DC have been
found recently to be involved in the induction of regulatory
tolerance [1].
TOLEROGENIC DC SUBSETS
Until recently, the immature developmental stages of DC dif-
ferentiation were believed to induce T cell anergy or Treg cells,
whereas DC, which are transformed into mature DC by virtue
of activation stimuli, were thought to represent immunogenic
DC capable of inducing strong, primary T cell responses (Fig.
1). This bimodal concept of immature versus mature DC has
been challenged recently by studies demonstrating that bone
marrow-derived, antigen-bearing mature DC can expand Treg
cells with suppressive properties in vitro and in vivo [2–5].
Steady-state, immature myeloid DC
The first evidence that immature DC are able to induce toler-
ance derives from studies showing that peripheral CD4 T
cells acquire regulatory properties after repeated in vitro stim-
ulation with immature DC [6]. These T cells were then able to
block the proliferation of conventional effector T cells. This
inhibition was mediated by cell–cell contact and was indepen-
dent of soluble mediators. These observations were confirmed
in in vivo models with OVA or hen egg lysozyme (HEL)
covalently linked to anti-DEC-205 antibodies and injected into
mice [7–9]. These antigen-antibody conjugates target the DC-
specific antigen receptor DEC-205, which mediates uptake and
presentation to OVA- and HEL-specific T cells without further
activating the DC in situ. The analysis of the immune re-
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sponses induced after targeting DC in the steady-state revealed
that tolerance was obtained. Possible mechanisms included the
disappearance of antigen-specific T cells [7, 8] and the induc-
tion of Treg cells [9]. These mechanisms are not mutually
exclusive, as induction of Treg cells was observed approxi-
mately 8 days after loading the DC in vivo, and T cell deletion
was recorded 3 weeks after the original challenge of the DC.
Although the exact mechanism of action is not yet clear, the
activation of these two pathways is corroborated further by
additional results. For example, the in vivo occurrence of
CD8 T cells with regulatory properties has been demonstrated
after injection of immature DC [10]. In contrast, direct “kill-
ing” of T cells by induction of apoptosis after contact with DC
has been reported by Suss and Shortman [11]. They showed
that a certain subtype of DC expresses the Fas ligand (FasL),
enabling these DC to kill Fas-bearing, activated T cells. More-
over, a subset of DEC-205/CD8 DC identified in mouse
spleens was shown to be able to curb proliferation of CD8 and
CD4 T cells in vitro [12–14].
Immature DC may function as “the police” of the immune
system, which actively maintains tolerance to self-antigens
derived from the processing and presentation of the apoptotic
cell. In general, when DC encounter apoptotic cells, a nonin-
flammatory and tolerogenic phenotype typical of immature DC
is observed [15]. For example, Stuart et al. [16] showed that DC
pretreated with apoptotic cells exhibited an impaired capacity
to stimulate T lymphocytes. In addition, Kim et al. [17] dem-
onstrated that phosphatidylserine from apoptotic cells induces
regulation of DC activation. Downstream events following ap-
optotic cell contact or phosphatidylserine contact with DC
resulted in the inhibition of IL-12p35 transcription and thus,
IL-12p70 synthesis [17]. In addition to maintaining an imma-
ture phenotype, exposure to apoptotic cells induces the expres-
sion of IL-6 and IL-12p40, further enhancing the tolerogenic
function of the DC. Consequently, differentiation of naı¨ve T
lymphocytes into type 1 effectors is suppressed [18].
Modulated, immature myeloid DC
Immature myeloid DC treated with agents, which inhibit their
maturation, acquire tolerogenic activity. Such agents include
vitamin D3 [19], immunosuppressive drugs (such as cyclospor-
ine) [20], and IL-10 [21], which inhibit differentiation, matu-
ration, activation, and survival of DC in vivo and in vitro,
leading to impaired activation of alloreactive T cells. The
secretion of IL-12 and proinflammatory cytokines and the
expression of costimulatory molecules are reduced significantly
in these modulated DC, resulting in an impaired capacity of
DC to induce allogeneic or autologous T cell activation [22].
The inhibitory effect of IL-10 on the APC function of DC is
attributed to the down-regulation of MHC-class II and costimu-
latory molecules and to the inhibition of inflammatory cytokine
synthesis inducing an antigen-specific anergy in alloreactive
and melanoma antigen-specific CD4 and CD8 T cells, and
the anergic CD8 cells lose their capacity to lyse target tumor
Fig. 1. Schematic representation of the interplay between tolerogenic DC subsets and Treg cells. (a) Tolerogenic DC are composed of different subsets of cells
with specific phenotypic profiles. (b) Fully mature DC express high levels of CD80/CD86 and HLA-DR, produce significant levels of IL-12, and stimulate T cell
immunity and vigorous T cell-proliferative responses (e), whereas tolerogenic DC induce suppressor T cells (c) and Treg cells (d) with an inherent, low ability to
proliferate in response to mitogens or antigens. Treg cells inhibit not only effector T cells but also act on DC to temper immunity efficiently. pDC, Plasmacytoid
DC; TSLP, thymic stromal lymphopoietin; Tr1, Treg 1 cell; sTGF-1, soluble TGF-1.
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cells [21, 23, 24]. Treatment of immature DC with TGF- and
IL-10 has been shown to have a similar effect, resulting in the
generation of CD4 and CD8 Treg cells [25]. It is important
that DC with properties similar to the IL-10-modulated DC
generated in vitro have also been detected in vivo in IL-10-
producing tumors [26].
Treg cell-treated, immature myeloid DC
Human CD8CD28 T cells are a distinct Treg cell popula-
tion, which suppresses antigen-specific CD4 T cell responses
by inhibiting their capacity to produce IL-2 and to up-regulate
CD40L expression [27]. Chang et al. [28] found that human
CD8CD28 T cells can modulate the function of immature,
monocyte-derived DC. These modulated DC do not express
CD80 and CD86 and are able to anergize alloreactive memory
CD4 T cells [28]. This suppressive effect by CD8CD28 T
cell-treated DC is MHC-restricted and antigen-specific. The
induction of CD4 T cell anergy is not caused by a suppressor
effect mediated by soluble factors but requires direct interac-
tions between effector CD4 T cells and pretreated DC. The
mechanism for generating tolerogenic DC has been analyzed
extensively in this system. Exposure of immature DC to
CD8CD28 T cells in an antigen-specific manner results in
interference with CD40–CD40L-mediated signaling, which
normally induces the functional maturation of DC and a high
level of expression of CD80 and CD86. Moreover, the tolero-
genic influence of CD8CD28 T cells is associated with the
induction of the inhibitory molecules Ig-like transcript 3 (ILT3)
and ILT4 at the DC surface [28]. It is interesting that
CD8CD28 T cells, which can up-regulate these molecules
in donor APC, are present in the circulation of human heart
transplant recipients, especially in rejection-free patients [28].
As with CD8CD28 Treg, CD4CD25 Treg cells have
been shown to act directly on DC in a cytokine-independent
manner, inducing the up-regulation of the inhibitory receptors
ILT3 and ILT4. These inhibitory receptors are crucial to the
tolerogenic phenotype acquired by DC, as the suppressive
effect of Treg cells on T cell proliferation can be abrogated by
antibodies to ILT3 and ILT4 [29].
Semimature myeloid DC
Lutz and Schuler [30] have described semimature DC, which
originate from the exposure of immature DC to tissue-derived
TNF- in the absence of a pathogenic motif. These cells
acquire part of the characteristics of fully mature DC, includ-
ing the expression of costimulatory molecules and the ability to
migrate to the draining lymph nodes. However, they produce
low levels of proinflammatory cytokines such as IL-1, IL-6,
TNF-, and IL-12p70. Semimature DC lack the capacity to
produce polarizing signals and as a consequence, predomi-
nantly drive the development of adaptive Treg cells. It is
important that on subsequent pathogenic challenge, such semi-
mature DC can still develop into fully immunogenic, IL-12-
producing mature DC, and they drive effector Th1 cell re-
sponses [30]. For example, in vitro-generated, peptide-loaded
DC, which have been matured by TNF- and subsequently
injected into mice, have been shown to act in a tolerogenic
manner by preventing experimental autoimmune encephalomy-
elitis through the induction of IL-10-producing CD4 Treg
cells [31, 32]. However, the mechanisms used to induce toler-
ance remained unclear [33].
Immature pDC
Immature pDC, freshly enriched from human peripheral blood,
can induce an anergic state in antigen-specific CD4 T cell
lines [34]. This effect is associated with a loss of IL-2 produc-
tion and is completely or partially reversible in the presence of
a high concentration of exogenous IL-2 in the secondary cul-
tures [34]. T cell anergy induction by immature pDC requires
cognate contact via TCR-MHC engagement [34]. This process
is cytokine-independent, but the precise interactions between
pDC and CD4 T cells, which induce T cell anergy, remain
unclear. The mechanism for T cell anergy induction could be
explained by TCR-MHC engagement without costimulatory
signals through CD80 and CD86, as freshly isolated pDC do
not express or express only minimal levels of CD80 and CD86
[35]. However, as CD40-activated mature pDC are also tolero-
genic, it is unlikely that their capacity to elicit the generation
of Treg cells is related only to inefficient T cell stimulation.
CD40L-activated pDC
The induction of tolerance versus immunity may not simply be
determined by the maturity of the DC. For example, naı¨ve
CD8 T cells primed with allogeneic, CD40L-activated pDC
differentiate into CD8 T cells, which display poor secondary-
proliferative and cytolytic responses. In addition, they produce,
respectively, high and low levels of IL-10 and IFN- upon
restimulation [36]. These IL-10-producing CD8 Treg cells
can be generated directly from naı¨ve CD8 T cells by a single
round of stimulation with mature pDC, and they share many
similarities with CD4 Treg cells. These CD8 Treg cells,
allostimulated with mature pDC, suppress primary T cell ac-
tivation through IL-10 secretion [36–38].
Mature DC
Current literature suggests that T cells recognizing antigen on
mature DC differentiate into effector T cells, whereas tolerance
is induced when antigen is presented by immature DC.
Liu [39] reported the only study of DC requirement for the
differentiation of Treg cells from the thymus. Within the me-
dulla of the human thymus, a subset of mature DC positively
selects Treg cells, protecting the medium to high-affinity, self-
reactive T cells from negative deletion and inducing their
differentiation into Treg cells in the thymus. How DC can have
a negative role in the deletion of high-affinity, self-reactive
thymocytes and simultaneously, a positive role in the selection
of high-affinity, self-reactive Treg cells seems to be a paradox
[39]. A recent study by Watanabe et al. [40] showed that the
epithelial cells within Hassall’s corpuscles are developmen-
tally programmed to express TSLP, which activates a subpopu-
lation of DC in the thymic medulla to express CD80 and CD86.
TSLP does not induce activated myeloid DC to produce proin-
flammatory cytokines such as IL-12, IL-6, TNF-, and IL-1.
Although the immature DC within the cortico-medullary junc-
tion may be critical for negative selection, TSLP-DC in the
central part of the medulla may be critical for the positive
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selection of high-affinity, autoreactive T cells and for their
differentiation into CD4CD25 Treg cells [40].
In the periphery, mature DC also expand functional Treg
cells. These latter cells may be important during infection,
when DC are presenting microbial antigens, as there is likely
a concomitant presentation of self and environmental antigens.
When mature DC are inducing immune responses in the lymph
node, with concomitant IL-2 production, bystander
CD25CD4 T cells would be expected to expand. In addition,
when maturing DC are themselves presenting cognate self-
antigens, thymic-derived CD25CD4 T cells would be ex-
pected to expand vigorously and to serve to suppress autore-
active responses by other DC [2, 41, 42]. Moreover, Verhasselt
et al. [43] observed that a significant fraction of CD4 T cells
cultured with mature, autologous DC acquired regulatory prop-
erties. Indeed, when added to an allogeneic MLR, these CD4
T cells suppressed the response of alloreactive T lymphocytes
to the priming DC [43].
FEATURES OF TOLEROGENIC DC
Tolerogenic DC subsets share common features, such as low
MHC expression and little or no expression of CD80 and
CD86, except for the CD40-activated mature pDC. They also
produce reduced levels of IL-12 and low amounts of costimu-
latory CD28L. The induction of Treg cells requires a direct
cell–cell contact between T cells and DC, and suppression of
T cells is MHC-restricted and antigen-specific. There are sev-
eral candidate molecules expressed by DC, which may induce
key signals to generate Treg cells, such as IL-10, programmed
death-ligand 1 (PD-L1), ILT3, ILT4, and indoleamine 2,3-
dioxygenase (IDO) [33, 44, 45].
The inhibitory receptors ILT3 and ILT4 belong to a family of
molecules, which are structurally and functionally related to
killer cell-inhibitory receptors, and they display a long, cyto-
plasmic tail containing immunoreceptor tyrosine-based inhib-
itory motifs. ILT3 and ILT4 mediate inhibition of cell activa-
tion by recruiting the tyrosine phosphatase Src homology-2-
containing tyrosine phosphatase 1 and interfere with CD40–
CD40L-mediated signaling. Although the ligand for ILT3 is
currently unknown, ILT4 bond HLA-A, -B, -C, and -G [28].
Recently, it has been demonstrated that the up-regulation of
ILT3 and ILT4 induced on DC upon interaction with suppres-
sor CD8CD28 T cells renders DC tolerogenic [46]. It is
interesting that similar effects are exerted by exogenous IL-10
and IFN- [47]. Blocking of the inhibitory receptors with
specific antibodies against ILT3 and ILT4 restores the stimu-
lating activity of the DC, preventing them from inducing T cell
anergy [48].
Another potentially important aspect of tolerogenic DC is
IDO, which catalyzes the depletion of the essential amino acid
tryptophan. This depletion enhances the production of immu-
noregulatory kynurenine metabolites, which inhibit T cell pro-
liferation, and induces T cell suppression by activation of
GCN2 kinase in T cells [49]. IDO expression is detected
constitutively in human regulatory pDC and can be induced by
classical DC maturation stimuli, namely IFN- and LPS or
PGE2, which contribute to their immunoregulatory capacity
[50]. Inversely, murine CD4CD25 Treg cells can help DC to
express functionally active IDO [51].
Other molecules, which are certainly promising for future
study, are novel, negative, costimulatory B7 family members
(reviewed in ref. [52]), including PD-L1 (also known as B7-
H1), B7-H3 (also known as B7RP-2), B7-H4 (also known as
B7S1 or B7x), and the ligand of the B and T lymphocyte
attenuator. Although glucocorticoid-induced TNFR (GITR) ex-
pression has been associated with activated, naturally occur-
ring Treg cells [53], more recent literature indicates that the
distribution of GITR expression is much wider and that GITR
ligation suppresses rather than induces tolerance [54]. Consid-
ering the wealth of negative regulatory molecules, it might be
anticipated that further subclassification of regulatory DC sub-
sets will be necessary in the near future.
TREG CELL POPULATIONS
Treg cells consist of different subsets of T lymphocytes char-
acterized by their ability to suppress proliferation of conven-
tional effector T cells by various mechanisms (see Communi-
cation between DC and Treg cells and regulatory functions
below).
The list of candidate markers for Treg cells increases con-
tinuously and includes CD45RB, CD103, or CD122 and the
transcriptional repressor forkhead box P3 (Foxp3) [55, 56],
which is currently considered as the most promising marker for
Treg cells. In addition, Treg cells are characterized by the
constitutive expression of GITR family-related protein, L-se-
lectin (CD62L), and CTLA-4 (or CD152) [57, 58]. Thus, no
specific marker (except the transcription factor Foxp3) has
been identified to date. In particular, no defined cell surface
molecules can be targeted with antibodies specifically to de-
plete or to purify these cells. This problem is an ongoing
challenge for the study and manipulation of these suppressive
cells. Concerning the Foxp3 itself, one question remains:
whether its expression is an absolute marker of Treg cells in
humans or mice. In the mouse, there is an excellent correlation
between the expression of Foxp3 and CD25, but a minor
population of Foxp3 cells is CD25–. In humans, almost all
CD4CD25hi cells are Foxp3, whereas a variable percentage
of CD25int cells expresses lower amounts of Foxp3. Moreover,
whereas the TGF--induced murine Foxp3 T cells manifest
suppressor activity in vitro and in vivo, Foxp3 expression in
human T cells does not correlate uniformly with suppressor
activity. In addition, populations of CD4CD25 Treg cells
producing IL-10 do not seem to express Foxp3 [59].
Over the past few years, several phenotypically distinct Treg
cell populations have been described [59–61] (Table 1). The
classic Treg cells are thymus-derived CD4CD25Foxp3 T
cells, and many investigators have termed these cells “natural”
Treg in contrast to Treg cells, which develop in peripheral
lymphoid tissues and are frequently Foxp3– and have been
termed “adaptive” or “induced” Treg cells. Several studies
have raised the possibility that CD4 Foxp3 cells might also
be generated in peripheral lymphoid tissues from naı¨ve CD4
Foxp3– progenitors [59].
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Among all the subsets described to date, the most studied
are the naturally occurring CD4CD25 Treg cells, the anti-
gen-induced CD4CD25 Treg cells, and the CD8CD28– T
cells (or T suppressive cells).
The naturally occurring CD4CD25 Treg cells represent a
small subset (5–6%) of the overall CD4 T cell population and
are generated in the thymus. They mediate immune suppres-
sion by inhibiting the activation and proliferation of Th and
cytotoxic T cells through a cell–cell contact and antigen-
nonspecific mechanism [67]. However, in some models,
Foxp3 natural Treg cells have been shown to be antigen-
specific [68], suggesting that the distinction between the dif-
ferent subsets of Treg cells is not at all clear and that the notion
of antigen induction is not adequate to distinguish the different
Treg cells.
The antigen-induced CD4CD25 Treg cells are detected
in peripheral tissues after MHC/peptide stimulation of conven-
tional CD4CD25– precursors [69]. These Treg cells include
Tr1 cells, secreting IFN-, IL-10, and to a lesser extent,
TGF-, and Th3 T cells, secreting high levels of TGF- and
IL-10 [70]. The suppressive activity of the antigen-induced
Treg cells is cell contact-independent and is mediated by the
release of TGF- and IL-10 [71]. Th3 and Tr1 cells display
suppressive properties on Th1 and Th2 cells, but only Th3
cells provide help for IgA synthesis [72]. Tr1 cells regulate the
function of naı¨ve and memory T cells in vitro and in vivo and
can suppress responses to tumors, alloantigens, and pathogens
[72]. These two subsets of Treg cells also differ in the expres-
sion of distinct integrins, mainly 41 and 47 [73], which
have been shown to be homing receptors for the migration of T
lymphocytes to inflamed tissues and to mucosal sites, respec-
tively [74]. These data suggest that 41
CD25 Treg cells
migrate in vivo to inflamed tissues, where they inhibit effector
T cell responses, whereas 47
CD25 Treg cells could pre-
vent chronic mucosal inflammations by counteracting autore-
active T cells.
It is generally understood that being CD4 T cells, naturally
occurring Treg cells as well as antigen-induced Treg cells need
to be activated by MHC class II-bound epitopes on DC. It is
widely believed that although antigen-induced Treg cells need
TCR ligands and costimulation, naturally occurring Treg cells
need only a TCR-driven signal for functional activation. None-
theless, as only a limited class of cells expresses MHC class II
molecules, naturally occurring Treg cells need DC for their
activation. Thus, just as DC are indispensable in activating,
naı¨ve effector T cells, they are also needed for the activation of
Treg cells [75].
A subpopulation of Treg cells expresses CD8 and can me-
diate immune suppression in an antigen-dependent manner
[76]. CD8 Treg cells suppress antigen-activated CD4 T cells
by a TCR/MHC class Ib molecule restriction [77]. CD8
CD28– Treg cells also suppress APC, which present the same
peptide/MHC complexes to which the CD8 Treg cells were
primed previously [78]. In contrast to naturally occurring
CD4 CD25 Treg cells, an important feature of CD8 Treg
cells is that they are generated or induced only after antigen
priming [79].
COMMUNICATION BETWEEN DC AND TREG
CELLS AND REGULATORY FUNCTIONS
There is accumulating evidence that tolerogenic DC can stim-
ulate Treg cell expansion (Fig. 2). For example, tumors con-
vert DC into TGF--expressing DC, which are capable of
promoting Treg cell proliferation [80]. In addition to expansion
TABLE 1. Subsets of T-cells









Markers CD25     – ND –
GITR  – ND   ND ND
CTLA-4      ND ND
CD62L    ND ND ND 
Foxp3  (?) (?)   ND –
IL-10
production
   ND   
TGF-
production


























Target cells T cells/APC T cells/APC T cells T cells DC/APC T cells/APC T cells
Suggested
origin
Thymus Periphery Periphery Thymus Periphery Periphery Periphery
References [40, 62] [63] [64] [65] [28] [38] [66]
(?), Not yet clear; ND, no data available.
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of Treg cells, DC can mediate the conversion of naı¨ve
CD4CD25– T cells. Kretschmer [81] reported the conversion
of truly naı¨ve CD4 T cells into suppressor cells expressing
Foxp3 by the targeting of peptide-agonist ligands to DC. The
conversion was achieved by minute antigen doses with subop-
timal DC activation. The addition of TGF- or the absence of
IL-2 production, which reduces proliferation, enhanced the
conversion rate [81].
Once activated in an antigen-specific manner by DC, Treg
cells might also suppress effector T cells, which are specific for
other antigens. This happens if these antigens are expressed by
the same APC or target cells, as well as by cells, which are in
close vicinity, a phenomenon known as bystander suppression
[82]. Suppressive mechanisms of Treg cells have been ad-
dressed using many in vitro and in vivo mouse models. Mul-
tiple suppressive mechanisms including cell–cell contact and
soluble factors have been proposed [83–85].
Activated human Treg cells express granzyme A and kill T
cells and APC through perforin [86]. However, another study
using granzyme B-deficient and perforin-deficient mice re-
ported that Treg cells mediate suppression through a granzyme
B-dependent but perforin-independent mechanism [60, 87].
Soluble factors and cell–cell contacts are involved in the
suppressive function of Treg cells. For example, competition
between Treg and conventional T cells for IL-2 has been
suggested as a suppressive mechanism [57, 88]. Besides their
role in the effector functions of T cells and in DC viability, Treg
cells also have a profound impact on DC function. In this
respect, human CD4CD25 Treg cells may render DC inef-
ficient as APC [89]. Treg cells are also able to enable DC to
express functional IL-10 [90]. CD4CD25 Treg cells have
been shown to inhibit the expression of CD80 and CD86
costimulatory molecules on DC in a CTLA-4-dependent way
[91, 92]. Treg cells impede DC function by down-regulating the
activation of NF-B. The suppression mechanism requires
TGF- and IL-10 and is associated with the induction of the
Smad signaling pathway and activation of the STAT3 transcrip-
tion factor [93].
Moreover, Sato et al. [94] showed that Treg cells suppress
CD25CD4 T cell responses, at least in part by inhibiting
IL-12 production from DC, and they themselves can undergo
proliferation with the mediation of CD25CD4 T cells in
vitro. These results offer a novel, negative-feedback system
involving a tripartite interaction among CD25CD4 and
CD25CD4 T cells and DC, which may contribute to the
termination of immune responses.
Another mechanism is the induction of IDO-expressing DC.
IDO is an enzyme that degrades the essential amino acid
tryptophan, which is required for T cell activation [95]. IDO
human DC reduce tryptophan, and as this amino acid is an
essential, proliferative stimulus for effector T cells, its defi-
ciency provokes T cell apoptosis and thus, promotes tolerance
in the tumor microenvironment (Fig. 3) [95]. Mouse CTLA-4
Treg cells mediate their suppressive activity by inducing the
expression of IDO in DC through CTLA-4 [96].
B7-H4 (also known as B7x, B7S1), which is a recently
discovered member of the B7 family of T cell costimulatory
molecules, regulates T cell responses negatively. It is interest-
ing that Treg cells, but not normal T cells, induce B7-H4
expression by DC and render them immunosuppressive [97].
CD4CD25 Treg cells can convey suppressor activity to
conventional CD4 T cells, a phenomenon consequently called
infectious tolerance [98, 99]. Human CD4 T cells, which have
been cocultured with CD4CD25 Treg cells after isolation,
are able to suppress the proliferation of freshly prepared,
conventional CD4 T cells. This “infectious” suppressor func-
tion, transferred from CD4CD25 Treg cells, has been shown
to be cell contact-dependent and partially mediated by TGF-
[99]. However, there are also indications that CD4CD25
Treg cells can mediate their suppressor activity via the release
of IL-10 [100–102].
Suciu-Foca et al. [29] described a cascade of suppression
where allospecific CD8CD28 Treg cells first tolerize the DC.
These tolerized DC anergize alloreactive CD4 T cells, which
recognize MHC class II alloantigens on their membrane-induc-
ing Treg cells. In turn, these Treg cells tolerize fresh DC.
Finally, DC tolerized by the CD4CD25 Treg cells may
inhibit the alloreactivity of other CD4 T cells, thus continuing
the T suppressor cell cascade. These tolerized DC with up-
Fig. 2. Schematic representation of the interplay between DC and Treg cells.
Environmental factors and Treg cells may alter the function of DC. The
mechanisms responsible for the induction of tolerogenic DC by Treg cells are
multifactorial and include the production of IL-10 or TGF-, the induction of
B7-H4 expression, the engagement of CD80, or the up-regulation of ILT3 and
ILT4. These tolerogenic DC may subsequently promote Treg cell differentia-
tion and/or expansion and induce T cell anergy or apoptosis by the production
of IDO by tolerogenic DC. Activated Treg cells may also kill target cells
directly (T cells or DC) through perforin or granzyme B-dependent pathways.
VEGF, Vascular endothelial growth factor.
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regulated expression of the inhibitory receptors ILT3 and ILT4
spread the unresponsiveness to antigen-specific T cells.
In conclusion, Treg cells control the expansion of effector T
cells, which respond to self and nonself antigens through a
variety of mechanisms, including cognate or noncognate inter-
actions with DC or activated effector T cells, direct regulation
by the killing of undesirable T cell specificities, or secondary
activation of new Treg cell subsets. In addition to T cells, Treg
cells can therefore temper immunity by targeting DC, and
multiple Treg cell-mediated, suppressive mechanisms are
likely to be operative in vivo.
BENEFICIAL AND ADVERSE EFFECTS
OF THE CROSS-TALK BETWEEN DC
AND TREG CELLS
There is convincing evidence that Treg cells play a protective
role against autoimmune diseases, allograft rejections, and
allergic conditions, where they suppress potentially patho-
genic, immune responses mediated by effector Th1 cells, Th2
cells, or CTLs [103, 104]. As these effector T cell responses
also play an important role in the protection against pathogens,
it might seem counterintuitive that Treg cells could have a
protective role in infection. However, in many infectious dis-
eases, important collateral damage to host tissues potentially
induced by immune responses against pathogens is prevented
by immunoregulatory mechanisms, including the induction of
Treg cells [105]. Moreover, recent studies suggest that Treg
cells can recognize microbial antigens and that this recognition
is associated with their function [68]. Although Treg cells are
beneficial to the host by preventing immunopathology and
enabling the development of immune memory, they can also be
beneficial to the pathogen, enabling it to establish a chronic
infection. Many pathogens have evolved strategies that facili-
tate their persistence, largely through their ability to evade or
subvert the host immune response. One strategy is to induce a
state of immunosuppression through direct interference with
host immune effector mechanisms or through the production of
immunosuppressive cytokines. For example, distinct families
of pathogen-derived molecules, including filamentous hemag-
glutinin and adenylate cyclase toxin from Bordetella pertussis,
cholera toxin, hepatitis C virus nonstructural protein 4, and
Schistosoma mansoni-specific phosphatidylserine, interact with
pattern recognition receptors, including CD11b–CD18, gangli-
oside GM1, or TLR2 on the surface of DC. These interactions
stimulate IL-10 production and inhibit IL-12 production by
macrophages and DC and activate DC to become semimature
and to promote the induction of Treg cells (for review, see ref.
[105]).
Treg cells are also implicated in the tolerance against com-
mensal microorganisms and innocuous agents in the gastroin-
testinal system or in the respiratory tractus [106, 107]. Indeed,
mucosal surfaces are obligatory sites for tolerance induction
against numerous exogenous antigens. Therefore, the mucosal
surface seems to provide a microenvironment, where IL-10 and
TGF- are highly expressed, DC effector functions affected,
and Treg cells induced [108].
It is interesting that Treg cells are thought to have an
enormous potential in suppressing pathological immune re-
sponses in transplantation. Treg cells have been described in
tolerated tissues, such as accepted skin grafts. T cells from
such tolerated tissues can repopulate the peripheral immune
system of immunodeficient recipients and prevent graft rejec-
tion by naı¨ve T cells [109].
An emerging model of Treg cell action is that organ-specific
Treg cells acquire suppressive activity through activation by
DC expressing organ-derived antigens. Thus, the efficacy of
Treg cell-based therapy should be increased by using organ-
specific Treg cells rather than polyclonal Treg cells. This
necessitates the ability to identify relevant antigens and to
expand rare, antigen-specific Treg cells from diverse poly-
clonal populations. Yamazaki et al. [2] showed in a mouse
model that DC are able to expand antigen-specific Treg cells,
Fig. 3. Treg cells inhibit effector T cells via the induction of IDO. The expression of IDO by DC is mediated partially by the interaction of CTLA-4 expressed
on Treg cells and B7 expressed on DC. IDO catalyzes the degradation of tryptophan, which is an essential, proliferative stimulus for effector T cells and leads to
the apoptosis of these cells in a tryptophan-deprived environment.
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particularly polyclonal Treg cells directed to alloantigens.
When triggered by specific antigen, these Treg cells act back
on immature DC to block the up-regulation of CD80 and CD86
costimulatory molecules.
Serial studies of the phenotype displayed by T cells from
heart allograft recipients have demonstrated a significant in-
crease of the CD8CD28CD27 perforin-negative T cell
population in rejection-free patients [110]. The Treg cells from
these recipients inhibited the up-regulation of CD80 and CD86
on CD40-ligated DC from the donor. This inhibitory effect is
MHC class I-allorestricted, demonstrating the antigen speci-
ficity of these in vivo-generated Treg cells [111]. Treg cells
from these patients also induced the up-regulation of ILT3 and
ILT4 on donor DC. Serial determination of the suppressor
activity displayed by CD4CD25 T cells of patients yielded
similar results. However, CD4CD25 Treg cells become de-
tectable at later times following transplantation. The persis-
tence of allospecific Treg cells in rejection-free patients late
after transplantation indicates that these T cells, which inhibit
the direct, allorecognition pathway, are stimulated continu-
ously by donor APC. However, as donor DC migrate out of the
graft during the early post-transplantation period, it is likely
that they are stimulated by endothelial cells of the transplant,
which are known to act as semiprofessional DC [112].
In contrast to their protective role in autoimmune diseases,
Treg cells are likely to interfere negatively with immunity
against a wide variety of human tumors. Numerous studies in
recent years have described an increased frequency of
CD4CD25 T cells, and some or all of the characteristics of
Treg cells were in the blood and the tumor microenvironment
of patients with cancers originating in the head and neck [113],
lung [114, 115], liver [116], gastrointestinal tract [117, 118],
breast [119, 120], or skin [121]. Moreover, Treg cells with
specificity for antigens expressed by human tumors have been
identified recently [85, 122], and the extent of Treg cell accu-
mulation in tumor tissues has been shown to predict poor
survival [123]. Tumor environmental factors such as IL-10,
TGF-, VEGF, and PGs suppress DC differentiation and func-
tion, resulting in immature and/or partially differentiated DC
[124]. These tumor-converted DC are able to promote Treg cell
expansion or proliferation [80]. In addition to this induction of
tolerogenic DC, Treg cells themselves might be recruited by
tumors and secondarily, can alter the DC function, activating
the suppressor cascade [125].
Whereas Treg cells can impede anticancer surveillance
activities, it is likely that suppression of active inflammation by
these cells can prevent or control inflammation-associated
cancer [126, 127].
Autoimmune diseases develop as a consequence of break-
down in central and/or peripheral tolerance. Treg cells may
function in vivo by interrupting the effector development pro-
gram through limiting the autoreactive T cell access to DC. In
this context, failure of Treg cells to maintain tolerance may be
the underlying cause of autoimmune diseases [128]. In psori-
asis, it was found that a CD4 T lymphocyte subpopulation in
peripheral blood or in psoriatic plaques, phenotypically resem-
bling Treg cells (CD25high, CTLA-4, Foxp3high), was deficient
in its suppressor activity. This was associated with accelerated
proliferation of CD4 responder T cells in psoriasis [129].
Thus, it is speculated that this dysfunction in the skin and in
the blood of psoriatic patients may cause hyperproliferation of
psoriatic, pathogenic T cells in vivo.
THERAPEUTIC STRATEGIES
The manipulation of the DC–T cell interactions using different
pharmacological or biological agents could be exploited to
improve antitumor strategies or to control a variety of chronic
inflammatory conditions, such as autoimmune diseases, post-
transplantation graft-versus-host disease (GVHD), and allo-
graft rejection.
Treg cells can be expanded by ex vivo cultures with alloge-
neic splenocytes and IL-2, and the administration of these cells
at the time of grafting delays or prevents GVHD [130]. The
addition of TGF- in the ex vivo cultures has been shown to
enhance the functionality of Treg cells strongly [131]. The
observation that Treg cells expressing high levels of CD62L
inhibit GVHD lethality efficiently suggests that they can act in
secondary lymphoid tissues [132] in addition to the GVHD
target tissues such as skin, liver, lung, and the gastrointestinal
tract. In this regard, expression of the chemokine receptor
CCR5 by Treg cells was shown to play a critical role in the
migration to target tissues and to improve survival significantly
after donor lymphocyte infusion [133]. However, a major lim-
itation for the current therapeutic use of Treg cells is the
difficulty to obtain sufficient amounts of these relatively rare
cells from a single donor.
DC also serve as potential targets for suppression of alloim-
mune reactivity and promotion of tolerance induction. Indeed,
the DC-mediated immune regulation (i.e., expansion/induction
of Treg cells, such as CD4CD25 T cells or Tr1 cells, which
produce IL-10) is an important mechanism by which DC exert
their tolerogenicity. In transplantation, one of the potential
difficulties associated with the administration of immature,
regulatory DC is that in the context of the danger signals
related to surgical trauma and ischemia-reperfusion injury, the
administered DC may mature and accelerate graft rejection or
at least be unable to diminish immune alloresponses. This
problem could be overcome if the regulatory DC were admin-
istered before the transplantation. As demonstrated in most
experimental animal models, this approach could help the DC
to exert their tolerogenic effects by the time of transplantation.
A potential solution to decrease the risk of DC maturation
induced by the inflammatory environment is to manipulate the
DC in vitro to produce maturation-resistant, immature DC or
“alternatively activated” DC with stable, tolerogenic proper-
ties. Presently, the enhancement of DC tolerogenicity was
achieved by the use of pharmacological inhibition of DC mat-
uration or by the use of genetically engineered DC expressing
immunosuppressive molecules [134]. A novel strategy involv-
ing the use of DC for the regulation of T cell responses consists
of the generation of cytokine-modified regulatory DC. Several
growth factors, including IL-10, TGF-, G-CSF, hepatocyte
growth factor (HGF), and vasoactive intestinal peptide (VIP),
may modulate DC maturation and favor the differentiation of
tolerogenic DC [135]. In particular, DC differentiated in the
presence of exogenously added TGF-, IL-10, GM-CSF, and
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IL-4 possess the immunophenotypic and functional features of
immature DC and induce CD4CD25 Treg cells, which sup-
press the response of antigen-primed CD4 T cells to alloge-
neic, normal mature DC [136]. In addition, the release of
proinflammatory cytokines, i.e., IL-1, IL-6, TNF-, and most
markedly, IL-12, is abolished after IL-10 treatment [137]. The
therapeutic use of IL-10 is promising, as the injection of
IL-10-modified DC has been shown to be able to prevent
autoimmunity in a murine model of multiple sclerosis [138] or
to prolong graft survival [139]. Although most of these results
were obtained with DC exposed to IL-10 in vitro, there is also
recent evidence that IL-10-driven DC modulation may play a
role in the generation of Treg cells in vivo [140, 141]. In
addition to IL-10, TNF- may play a role in the induction of
tolerogenic DC [32]. Gonzalez-Rey et al. [142] have shown that
the injection of VIP-induced regulatory DC improves the clin-
ical severity of inflammatory bowel diseases. The therapeutic
effect was associated with the generation of IL10 Treg cells
with suppressive capacity on autoreactive T cells.
The role of immunosuppressive drugs in the induction of
regulatory DC was reviewed extensively elsewhere [134].
Among them are the vitamin D3 metabolite 1,25-(OH)2D3,
N-acetyl-l-cysteine, and common immunosuppressive drugs,
such as corticosteroids, cyclosporin A, rapamycin, and aspirin
[22, 143–145]. All of them interfere with DC differentiation
and maturation and consecutively, induce Treg cells. Cortico-
steroids do not affect DC viability but down-regulate the ex-
pression of costimulatory molecules on DC, prevent DC mat-
uration, and impair their immunostimulatory activities by in-
hibiting the NF-B pathway. Glucocorticoids also inhibit LPS-
or CD40L-induced DC maturation and DC production of IL-12
and TNF-. DC exposed to dexamethasone fail to prime Th1
cells efficiently, and the repeated stimulation of T cells with
these DC generates IL-10-producing Treg cells.
The modulation of costimulatory molecule expression on DC
is another way to induce the expansion of Treg cells, and the
blocking of molecules of the B7 family, including B7-1, B7-2,
or CTLA-4, has been used successfully for inducing immuno-
logic tolerance in vitro [146].
Recent data suggest that Treg cells expanded with DC are
able to suppress autoimmune diseases in vivo. For example,
islet autoantigen-specific murine Treg cells can be expanded
ex vivo by culturing CD25 CD4 T cells from diabetics
diagnosed recently with DC, loaded with islet antigens derived
from islet tissues or from peptide mixtures of identified autoan-
tigens [42]. Moreover, the injected Treg cells induce new Treg
cells in vivo directly, by expansion or differentiation through
cytokines or costimulatory molecules, or indirectly, by licens-
ing DC to induce the differentiation of new Treg cells (Fig. 4)
[147]. The advantage of directing therapy to specific antigens is
the avoidance of generalized immunosuppression. However,
the potential disadvantage is the possibility that generating
tolerance to one antigen may not block a disease mediated by
T cells with many specificities.
Strategies aiming to suppress tumor tolerance by inducing
the maturation of DC in vivo are also under active investiga-
tion. In this context, tumor-specific CTL, which do not lead to
an adequate anti-tumor response as a result of the presence of
Treg cells, may be activated to eradicate established tumors
[148, 149]. Simple vaccines have been described already,
Fig. 4. Therapeutic strategies in the context of autoimmune diseases and allograft rejection. DC are manipulated in vitro to produce maturation-resistant DC with
stable tolerogenic properties by the use of pharmacological inhibitors of DC maturation (IL-10, TGF-, G-CSF, GM-CSF, HGF, VIP, immunosuppressive drugs)
and serve to the expansion/induction of Treg cells. Conversely, Treg cells can also be expanded by ex vivo cultures with IL-2, TGF-, or DC and have inhibitory
effects on autoreactive T cells.
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which take advantage of CpG DNA motifs (a TLR9 agonist)
coinjected with or conjugated to a protein antigen [150, 151].
Vaccination with heat shock protein (HSP)-peptide complexes
can similarly stimulate the maturation of DC in vivo and induce
immunologic and clinical responses in melanoma patients
[152]. Ex vivo-derived DC may become mature in situ by
preconditioning the injection site with TLR agonists [153]. DC
can also be activated at the site of maturation through the
coexpression of local costimulatory molecules, proinflamma-
tory cytokines, and TLR agonists (Fig. 5) [154]. Recently, Nair
et al. [155] showed that vaccination of mice against Foxp3,
using Foxp3 mRNA-transfected DC, is capable of stimulating
specific CTL, which cause the preferential depletion of Foxp3-
expressing Treg cells in tumors but not in the periphery.
CONCLUSIONS
Currently, there is growing evidence that several factors, such
as the cell surface phenotype, maturation status, and immuno-
logical context, may determine whether a DC is tolerogenic or
immunogenic. Because of the ability of several DC populations
to induce antigen-specific Treg cells, manipulation of tolero-
genic DC is a potential strategy to suppress harmful T cell
responses in patients with autoimmune and allergic diseases as
well as those who experience transplant rejection.
However, tolerance is also considered as a potential obstacle
to tumor immunotherapy, as the suppressive milieu present
within established tumors may inhibit effective immune re-
sponses. Promising protocols should emerge in the future to
shift the balance back to a proinflammatory environment, to
promote DC activation, and to enhance anti-tumor immunity.
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